Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model

Radium-223 dichloride and enzalutamide are indicated for metastatic castration-resistant prostate cancer and their combination is currently being investigated in a large phase 3 clinical trial. Here, we evaluated the antitumor efficacy of radium-223, enzalutamide, and their combination in the intrat...

Full description

Bibliographic Details
Main Authors: Mari I. Suominen, Matias Knuuttila, Christoph A. Schatz, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen, Arne Scholz
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:International Journal of Molecular Sciences
Subjects:
radium-223
enzalutamide
prostate cancer
targeted alpha therapy
bone metastases
CRPC
Online Access:https://www.mdpi.com/1422-0067/24/3/2189

Internet

https://www.mdpi.com/1422-0067/24/3/2189

Similar Items